Clinical Experiences With Nivolumab/Relatlimab for Metastatic Melanoma
Source: Targeted Oncology, November 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, asked several participants to share their experiences treating patients with metastatic melanoma with nivolumab plus relatlimab. This is the second of 2 articles based on this event.
DISCUSSION QUESTION
What is your experience with nivolumab plus relatlimab-rmbw (Opdualag)? Have you used it in a clinical trial or in a real-world practice setting?
HUSSEIN TAWBI, MD, PHD: Nivolumab and relatlimab is now a fixed-dose combination that’s FDA approved, based on RELATIVITY-047 [NCT03470922]. Half of you have used it as a standard of care, and the other half hasn’t. Dr Ramadoss, tell us more about your experience.